Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 4Nivolumab 3spartalizumab 1regorafenib 1obinutuzumab 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1durvalumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Paclitaxel 1NEO212 1Lopinavir 1LGK974 1Itraconazole 1Isotretinoin 1Ipilimumab 1Interferon-alpha 1Immunohistochemistry 1IFL protocol 1House Calls 1Home Care Services 1Carboplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × LGK974 × Dermatologic × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡